Arcus Biosciences
RCUS
15.62
-0.16
-1.01%
Arcus Biosciences
US · RCUS
#2467 by market cap
Listed 2018
15.62
-0.16
-1.01%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:39
Recent news
-
Rating change
H.C. Wainwright Maintains Arcus Biosciences(RCUS.US) With Buy Rating, Maintains Target Price $45Market Newswire · 2026/9/26
-
Rating change
BofA Securities Maintains Arcus Biosciences(RCUS.US) With Hold Rating, Raises Target Price to $29Market Newswire · 2026/8/3
-
Wedbush Maintains Arcus Biosciences(RCUS.US) With Buy Rating, Raises Target Price to $45Market Newswire · 2026/11/5
-
Rating change
A Quick Look at Today's Ratings for Arcus Biosciences(RCUS.US), With a Forecast Between $42 to $45Market Newswire · 2026/8/7
-
Rating change
Morgan Stanley Downgrades Arcus Biosciences(RCUS.US) to Hold Rating, Maintains Target Price $23Market Newswire · 2026/10/22
-
Rating change
Citi Maintains Arcus Biosciences(RCUS.US) With Buy Rating, Maintains Target Price $45Market Newswire · 2026/9/10
-
Wedbush Maintains Arcus Biosciences(RCUS.US) With Buy Rating, Maintains Target Price $43Market Newswire · 2026/9/30
-
Rating change
J.P. Morgan Initiates Arcus Biosciences(RCUS.US) With Buy Rating, Announces Target Price $41Market Newswire · 2026/10/14
-
Rating change
Goldman Sachs Maintains Arcus Biosciences(RCUS.US) With Buy Rating, Raises Target Price to $42Market Newswire · 2026/8/8
-
Rating change
Analysts Are Bullish on Top Healthcare Stocks: Arcus Biosciences (RCUS), Prime Medicine, Inc. (PRME)TipRanks · 2026/9/25
-
Rating change
BofA Securities Maintains Arcus Biosciences(RCUS.US) With Hold Rating, Maintains Target Price $29Market Newswire · 2026/10/5
-
Rating change
TD Cowen Initiates Arcus Biosciences(RCUS.US) With Buy RatingMarket Newswire · 2026/9/16
-
Rating change
Goldman Sachs Maintains Arcus Biosciences(RCUS.US) With Buy Rating, Maintains Target Price $42Market Newswire · 2026/10/20
-
Rating change
A Quick Look at Today's Ratings for Arcus Biosciences(RCUS.US), With a Forecast Between $23 to $50Market Newswire · 2026/10/21
-
J.P. Morgan Maintains Arcus Biosciences(RCUS.US) With Buy Rating, Cuts Target Price to $40Market Newswire · 2026/11/9
-
Rating change
LifeSci Capital Maintains Arcus Biosciences(RCUS.US) With Buy Rating, Maintains Target Price $46Market Newswire · 2026/9/28
-
Morgan Stanley Maintains Arcus Biosciences(RCUS.US) With Hold Rating, Maintains Target Price $23Market Newswire · 2026/11/6
-
Citi Maintains Arcus Biosciences(RCUS.US) With Buy Rating, Maintains Target Price $50Market Newswire · 2026/11/5
-
Rating change
Truist Financial Downgrades Arcus Biosciences(RCUS.US) to Hold Rating, Raises Target Price to $41Market Newswire · 2026/10/22
-
Rating change
Truist Financial Maintains Arcus Biosciences(RCUS.US) With Buy Rating, Announces Target Price $40Market Newswire · 2026/9/8
-
Rating change
Wedbush Maintains Arcus Biosciences(RCUS.US) With Buy Rating, Maintains Target Price $41Market Newswire · 2026/7/23
-
Arcus Biosciences: Offering Expected to Close Oct. 23 RCUSDow Jones · 2026/10/22
-
Rating change
Truist Financial Maintains Arcus Biosciences(RCUS.US) With Buy RatingMarket Newswire · 2026/7/23
-
Citi Maintains Arcus Biosciences(RCUS.US) With Buy Rating, Maintains Target Price $50Market Newswire · 2026/10/26
-
Goldman Sachs Maintains Arcus Biosciences(RCUS.US) With Buy Rating, Maintains Target Price $42Market Newswire · 2026/10/14
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 19:39:06 · For reference only, not investment advice and not tailored to your situation.
Arcus Biosciences discussion 0 comments